share_log

Needham Maintains Buy on Recursion Pharmaceuticals, Lowers Price Target to $15

Benzinga ·  Nov 9, 2023 17:56

Needham analyst Gil Blum maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and lowers the price target from $17 to $15.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment